In analytical research, verifying sequence integrity, exact molecular weight, and strict purity metrics is critical before initiating any in vitro or animal study. This technical documentation provides a detailed breakdown of the CJC-1295 No DAC Certificate of Analysis (COA), explaining analytical methodologies like RP-HPLC and mass spectrometry to ensure uncompromising quality for laboratory evaluation.
In analytical research, verifying sequence integrity, exact molecular weight, and strict purity metrics is critical before initiating any in vitro or animal study. This technical documentation provides a detailed breakdown of the CJC-1295 No DAC Certificate of Analysis (COA), explaining analytical methodologies like RP-HPLC and mass spectrometry to ensure uncompromising quality for laboratory evaluation.
A CJC-1295 No DAC Certificate of Analysis (COA) is an independent laboratory document verifying the chemical identity, purity percentage, and safety parameters of synthetic CJC-1295 without Drug Affinity Complex. Essential COA metrics include reverse-phase high-performance liquid chromatography (RP-HPLC) purity analysis showing ≥99% target peptide area, electrospray ionization mass spectrometry (ESI-MS) confirming exact molecular weight, and chromogenic LAL assays quantifying endotoxin levels below 0.1 EU/mg.
When acquiring compounds for scientific inquiry, relying on verified batch analytical reports prevents experimental variance caused by synthesis byproducts, truncated peptide sequences, or residual organic solvents. Qualified investigators can access batch-matched documentation directly on the CJC-1295 No DAC product page or explore our broader catalog of research peptides for comprehensive analytical records.
CJC-1295 No DAC, frequently identified in literature as Modified GRF (1-29), is a tetrasubstituted 29-amino-acid peptide analog of endogenous Growth Hormone-Releasing Hormone (GHRH). The chemical formula for CJC-1295 No DAC is C152H252N44O42, featuring a calculated molecular mass of approximately 3367.9 g/mol. Endogenous GHRH contains 44 amino acids, but the N-terminal 29-amino-acid fragment retains full biological activity at the growth hormone-releasing hormone receptor (GHRHR).
To enhance metabolic stability in experimental models, four specific amino acids within the natural sequence are substituted: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These specific modifications inhibit enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV), a primary serum protease that rapidly inactivates native GHRH. Preclinical studies suggest that this altered structure prolongs the functional half-life of the molecule from approximately 5-10 minutes (native GHRH) to roughly 30 minutes in plasma, maintaining a physiologic, pulsatile secretion profile of growth hormone in rodent and mammalian assays.
Unlike formulations incorporating the Drug Affinity Complex (DAC)—which covalently binds to serum albumin to extend half-life to several days—CJC-1295 No DAC preserves a shorter, biological pulse dynamics. For a deeper technical exploration of receptor binding dynamics across GHRH analogs, review our GHRH analog mechanism studies.
Evaluating a Certificate of Analysis requires systematic verification of several key analytical metrics. Third-party testing laboratories utilize standardized chromatographic and spectroscopic instruments to generate objective data regarding sample composition:
1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): RP-HPLC separates the target peptide from synthesis impurities, deleted sequences, and side-reaction products based on hydrophobic interactions. The chromatogram displays retention time on the X-axis and UV absorbance (typically measured at 214 nm or 220 nm) on the Y-axis. Peak area integration determines the relative purity percentage. Laboratories should demand a main peak integration representing ≥99.0% of the total integrated peak area.
2. Electrospray Ionization Mass Spectrometry (ESI-MS): Mass spectrometry confirms identity by measuring the mass-to-charge ratio (m/z) of ionized molecules. A verified COA displays single-charged, double-charged, or triple-charged ion peaks (such as [M+2H]2+ or [M+3H]3+) that mathematically calculate back to the theoretical monoisotopic mass of 3367.9 Da. Exact mass matching confirms that the amino acid sequence was synthesized accurately without missing residue steps.
3. Bacterial Endotoxin Quantitation (LAL Assay): Endotoxins (lipopolysaccharides derived from Gram-negative bacterial cell walls) present significant confounding variables in cell culture and animal studies by triggering non-specific inflammatory signaling pathways. PX1 Research mandates that every batch undergoes Limulus Amebocyte Lysate (LAL) testing, establishing endotoxin content strictly below 0.05 EU/mg.
4. Trifluoroacetic Acid (TFA) and Moisture Content: Synthetic peptides purified via RP-HPLC contain residual TFA counter-ions. Moisture and TFA testing (via Karl Fischer titration and ion chromatography) ensure net peptide content is accurately quantified, guaranteeing that research dosing calculations reflect pure peptide weight rather than residual water or salt content. Learn more about testing standards in our guide to RP-HPLC and Mass Spectrometry validation.
In vitro assays and preclinical animal models heavily utilize CJC-1295 No DAC to investigate somatotroph axis regulation, intracellular signaling cascades, and downstream anabolic signaling pathways. By selectively binding to the GHRH receptor on anterior pituitary cells, the peptide stimulates adenylate cyclase activity, elevating intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA).
Preclinical studies indicate that this signaling cascade promotes the transcription and pulsatile exocytosis of stored Growth Hormone (GH). Downstream of GH elevation, animal models demonstrate increased hepatic expression and peripheral circulation of Insulin-like Growth Factor 1 (IGF-1). Researchers frequently evaluate CJC-1295 No DAC in experimental models focusing on:
• Muscle tissue regeneration and nitrogen retention dynamics in rodent models of sarcopenia or catabolic stress.
• Extracellular matrix remodeling, collagen deposition, and tendon-to-bone healing protocols in preclinical orthopeadic models.
• Cellular metabolic rate, lipolysis regulation, and mitochondrial density assays in cultured adipocytes and myocytes.
• Somatotrophic neuroprotection and pituitary feedback inhibition pathways under varied metabolic conditions.
Researchers seeking broader context on peptide-mediated growth factor pathways can explore our curated collection of growth hormone secretagogue literature.
When designing preclinical protocols targeting the somatotrophic axis, investigators must evaluate distinct secretagogue classes, structural variations, and kinetic profiles. CJC-1295 No DAC occupies a unique position as a GHRH receptor agonist, but its experimental behavior differs significantly from both long-acting analogs and growth hormone secretagogue receptor (GHSR) agonists.
For instance, CJC-1295 DAC contains a reactive lysine residue linked to maleimidopropionic acid. This addition enables bioconjugation to circulating albumin in vivo, extending the elimination half-life from ~30 minutes to over 6 days. While CJC-1295 DAC generates continuous, non-pulsatile elevations in GH and IGF-1, CJC-1295 No DAC produces transient, episodic GH spikes that mimic physiological secretion rhythms.
Similarly, comparing CJC-1295 No DAC with first-generation analogs like Sermorelin acetate reveals structural stability differences. Sermorelin represents the native 1-29 sequence without DPP-IV-resisting amino acid substitutions, resulting in rapid enzymatic cleavage in vivo (~8–12 minutes). On the other hand, co-administering GHRH analogs alongside selective ghrelin mimetics such as Ipamorelin demonstrates potent synergistic growth hormone release in preclinical rodent studies, as the two classes act through distinct, non-competing receptor systems (GHRHR vs. GHSR-1a).
For comprehensive technical protocols and comparative documentation across all secretagogue classes, visit the PX1 Research documentation hub.
To maintain the structural stability and target binding affinity indicated on the Certificate of Analysis, rigorous laboratory handling standards must be maintained during storage and reconstitution.
Lyophilized Storage: Upon delivery, lyophilized CJC-1295 No DAC should be stored in a dark, desiccated freezer environment at -20°C for short-term projects or -80°C for long-term storage. Under these conditions, the peptide remains stable for up to 24 months, preventing thermal degradation or hydrolysis.
Reconstitution Protocol: Reconstitution should occur within a laminar flow hood using aseptic techniques. For standard analytical preparation, introduce bacteriostatic water (0.9% benzyl alcohol) or sterile deionized water along the internal glass vial wall. Avoid direct violent stream discharge onto the lyophilized cake.
Dissolution and Mixing: Gently swirl or roll the vial between the palms until the lyophilized powder dissolves into a clear, colorless liquid. Never vortex or vigorously shake peptide solutions, as mechanical shear forces can cause peptide denaturation, aggregation, or precipitation out of solution.
Reconstituted Storage: Once reconstituted, store liquid aliquots at 2°C to 8°C. To prevent freeze-thaw degradation cycles, divide reconstituted solutions into single-use micro-centrifuge tubes if long-term frozen storage is required. Reconstituted peptides kept at refrigerated temperatures should be used within 21 to 28 days.
PX1 Research operates under strict quality management frameworks to ensure every batch of CJC-1295 No DAC meets exacting analytical standards. All peptides offered across our catalog are manufactured in state-of-the-art, GMP-compliant facilities located strictly within the United States.
Following automated solid-phase peptide synthesis (SPPS) and preparative HPLC purification, finished lots undergo independent validation at an accredited ISO 17025 third-party analytical laboratory. Every batch receives a unique lot number that corresponds to a publicly accessible COA containing full-spectrum RP-HPLC chromatograms, mass spectrometry molecular weight verification, and chromogenic endotoxin assay data.
To ensure rapid delivery without exposing sensitive peptides to extreme thermal stress, PX1 Research dispatches orders same-day (Monday through Friday) directly from temperature-controlled fulfillment centers located in California and Arizona. Qualified academic, clinical, and industrial research teams can register for wholesale research accounts to obtain bulk lot testing records and direct institutional pricing.
What is the purity standard for PX1 Research CJC-1295 No DAC?
Every lot of CJC-1295 No DAC provided by PX1 Research must achieve a minimum target purity of ≥99.0% as determined by third-party Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC).
How do I verify the mass spectrometry results on a CJC-1295 No DAC COA?
The mass spectrum displays peak m/z ratios corresponding to ionized states of the peptide. Check that the calculated monoisotopic molecular weight matches the theoretical value of 3367.9 Da (±1 Da) for modified GRF (1-29).
What is the difference between CJC-1295 No DAC and CJC-1295 DAC?
CJC-1295 No DAC (Modified GRF 1-29) lacks the Drug Affinity Complex moiety, resulting in a short half-life (~30 minutes) and pulsatile secretagogue action. CJC-1295 DAC contains maleimidopropionic acid, which binds serum albumin to extend half-life to several days.
What are the bacterial endotoxin limits on PX1 Research COAs?
PX1 Research enforces strict endotoxin safety thresholds, requiring all peptide batches to test below 0.05 EU/mg via chromogenic Limulus Amebocyte Lysate (LAL) testing.
What solvent should be used to reconstitute CJC-1295 No DAC for lab assays?
For standard laboratory evaluation and cell culture assays, sterile bacteriostatic water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS, pH 7.4) is recommended depending on protocol requirements.
How should CJC-1295 No DAC be stored upon receipt?
Lyophilized vials should be stored at -20°C in a desiccated environment upon arrival. Reconstituted liquid solutions should be kept refrigerated at 2°C to 8°C and protected from light.
Where are PX1 Research peptides manufactured and tested?
All PX1 Research peptides are synthesized in USA-based, GMP-compliant facilities and undergo independent batch testing at ISO 17025 accredited third-party laboratories.
Can CJC-1295 No DAC be ordered for human or clinical administration?
No. All products sold by PX1 Research, including CJC-1295 No DAC, are strictly intended for laboratory research use only (in vitro and animal modeling) and are not for human or veterinary use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.